[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 2, 2008

The Hope and Fear of Rimonabant

Author Affiliations

Author Affiliations: Section of Cardiology, Denver Veterans Affairs Medical Center, Denver, Colorado; Department of Medicine, University of Colorado at Denver, Aurora (Dr Rumsfeld); Section of Cardiology, Ann Arbor Veterans Affairs Medical Center and Department of Medicine, University of Michigan, Ann Arbor (Dr Nallamothu).

JAMA. 2008;299(13):1601-1602. doi:10.1001/jama.299.13.1601

From a patient's perspective, the principal questions about medical therapeutics are “Will I live longer or feel better?” and “What are the risks?” Until answers about the benefits of treatment on meaningful patient outcomes as well as about the attendant treatment risks are available, therapies have no role in the clinical armamentarium. Yet the answers to these deceptively simple questions often remain uncertain, even for some therapies commonly used in medical practice. The 2 faces of uncertainty for new therapeutics are hope and fear. The hope is that a treatment will provide meaningful benefits on patient outcomes. The fear is that, pending robust outcome studies, the only documented “benefits” of treatment may be for surrogate measures that may not translate into better outcomes or that any benefit will come at the expense of unacceptable risks.

First Page Preview View Large
First page PDF preview
First page PDF preview
×